Aptuit to Divest Two Non-core Sites

Jan. 9, 2015

Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK, to Albany Molecular Research Inc. (AMRI), and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana, solid-state chemistry business for a total consideration of $60 million.

“The sale of these sites to AMRI is part of our strategy to divest non-core assets and invest in our core competency of integrated early discovery to mid-phase drug development," says Dr. Jonathan Goldman, CEO. "We will continue to deliver world-class drug discovery and development services from our fully integrated, former large pharma R&D center of excellence in Verona, Italy, and our internationally renowned API facility in Oxford, UK. This transaction, which is part of our strategic initiative to grow our integrated offerings, will facilitate reinvestment in our core competencies and allow us to further differentiate our existing, unique capabilities and pursue strategic acquisitions.”

Dr. Goldman explained that Aptuit’s reinvestment strategy will include targeted acquisitions to expand the company’s service offerings and capital expenditure at the Verona facility.

For more information about Aptuit, visit www.aptuit.com.